Evolution of Antiviral Drug Resistance in SARS-CoV-2
Viruses · 18.05.2025 · 17 (5) · 722
DOI: 10.3390/v17050722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 18.05.2025. Verfasst von Roy Dinata und 2 weiteren Autor:innen. Beteiligte Einrichtung: Animal Science Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Drug Resistance, Viral, COVID-19 Drug Treatment. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The COVID-19 pandemic has had a significant impact and continues to alarm the entire world due to the rapid emergence of new variants, even after mass vaccinations. There is still an urgent need for new antivirals or strategies to combat the SARS-CoV-2 infections; however, we have success stories with nirmatrelvir. Drug repurposing and drug discovery may lead to a successful SARS-CoV-2 antiviral; however, rapid drug use may cause unexpected mutations and antiviral drug resistance. Conversely, novel variants of the SARS-CoV-2 can diminish the neutralizing efficacy of vaccines, thereby enhancing viral fitness and increasing the likelihood of drug resistance emergence. Additionally, the disposal of antivirals in wastewater also contributes to drug resistance. Overall, the present review summarizes the strategies and mechanisms involved in the development of drug resistance in SARS-CoV-2. Understanding the mechanism of antiviral resistance is crucial to mitigate the significant healthcare threat and to develop effective therapeutics against drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Animal Science Research Center, Division of Animal Sciences, University of Missouri, Columbia, MO 65211, USA.
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Roy Dinata, Piyush Baindara, Santi M Mandal
Zitieren
APA
Dinata, R., Baindara, P., & Mandal, S. M. (2025). Evolution of Antiviral Drug Resistance in SARS-CoV-2. Viruses, 17(5), 722. https://doi.org/10.3390/v17050722
Vancouver
Dinata R, Baindara P, Mandal SM. Evolution of Antiviral Drug Resistance in SARS-CoV-2. Viruses. 2025;17(5):722. doi:10.3390/v17050722
BibTeX
@article{Dinata2025,
author = {Dinata, Roy and Baindara, Piyush and Mandal, Santi M},
title = {Evolution of Antiviral Drug Resistance in SARS-CoV-2},
journal = {Viruses},
year = {2025},
volume = {17},
number = {5},
pages = {722},
doi = {10.3390/v17050722}
}
EUVIMED